Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen
Pharma
Mirum gets 2nd indication for blockbuster hopeful Livmarli
FDA has OK'd Mirum’s Livmarli to treat the rare liver disease PFIC. The nod comes on top of another for Livmarli to treat Alagille syndrome in 2021.
Kevin Dunleavy
Mar 13, 2024 6:20pm
Ipsen's Onivyde combo approved in first-line pancreatic cancer
Feb 13, 2024 4:31pm
Roche, Exelixis combo triumphs in prostate cancer trial
Aug 21, 2023 9:57am
After much trial and error, Ipsen scores FDA nod for Sohonos
Aug 17, 2023 8:28am
Mirum ponies up $445M for 2 Travere liver disease drugs
Jul 18, 2023 8:00am
After Albireo buyout, Ipsen's Bylvay picks up new use
Jun 13, 2023 2:02pm